Combining causal and correlative approaches to discover response biomarkers to paclitaxel
“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.”
Credit: 2024 Moscona-Nissan et al.
“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.”
BUFFALO, NY- February 21, 2024 – A new research perspective was published in Oncotarget’s Volume 15 on February 8, 2024, entitled, “Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.”
As discussed in this new paper, researchers Alberto Moscona-Nissan, Karl J. Habashy, Victor A. Arrieta, Adam M. Sonabend, and Crismita Dmello from Universidad Panamericana School of Medicine, Northwestern University and Universidad Nacional Autónoma de México recently discovered a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment.
“To further evaluate the potential application of this biomarker in the clinic for patients with glioblastoma, a prospective validation in cohorts of patients with glioblastoma is essential and will be performed as part of our ongoing phase II clinical trial (NCT04528680).”
The validation of novel biomarkers of susceptibility to therapy is critical to elucidate the efficacy signal of therapeutic agents. This is especially important in the context of glioblastoma, where therapeutic benefit is variable and unpredictable, leading to negative trials, yet the outcome of subset of patients has outperformed expectations.
“Precision and personalized medicine can lead to a transition from a stochastic treatment response into predictable scenarios. Further identification of predictive biomarkers, validation, and study of combinations as predictive models is critical to generate a greater impact that can be translated to the bedside of patients.”
Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28549
Correspondence to: Crismita Dmello, Adam M. Sonabend
Emails: [email protected], [email protected]
Keywords: glioblastoma, predictive biomarker, CRISPR screen, paclitaxel
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
- X, formerly Twitter
- YouTube
- Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact [email protected].
Oncotarget Journal Office
6666 East Quaker Street., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
Journal
Oncotarget
DOI
10.18632/oncotarget.28549
Method of Research
Commentary/editorial
Subject of Research
People
Article Title
Combining causal and correlative approaches to discover biomarkers of response to paclitaxel
Article Publication Date
8-Feb-2024
